Intarcia Therapeutics

Quote






Settle down guys. No CRL yet but chance is high given the woes in Hayward. Blame TA in Hayward for fucking it all up as it was too late for TH and his cronies even with big pharma pedigrees to fix the absolute incompetences. Heard that TA having zero experience or vision tried to scale up prototype manual fill finish.

Sit back with some wine and bong hits cos it's gonna be ugly with well deserved heads rolling all over if we get the dreaded CRL.
 






anonymous said:
Settle down guys. No CRL yet but chance is high given the woes in Hayward. Blame TA in Hayward for fucking it all up as it was too late for TH and his cronies even with big pharma pedigrees to fix the absolute incompetences. Heard that TA having zero experience or vision tried to scale up prototype manual fill finish.

Sit back with some wine and bong hits cos it's gonna be ugly with well deserved heads rolling all over if we get the dreaded CRL.
Click to expand...

Is this the reason for the hold up in hiring? I was contacted four months ago by a recruiter for a regional reimbursement director role. I had three interviews, completed the survey and....wait for it...nothing. In the meantime I just accepted another offer.

I'm sure this might be a good role and a great company but I've moved on!
 


















anonymous said:
Is this the reason for the hold up in hiring? I was contacted four months ago by a recruiter for a regional reimbursement director role. I had three interviews, completed the survey and....wait for it...nothing. In the meantime I just accepted another offer.

I'm sure this might be a good role and a great company but I've moved on!
Click to expand...

Good for you! This POS hole is not worth it. Hang up on any recruiter who calls you for an "exciting opportunity at a biotech unicorn startup."

Ha. It's a 20 year old startup which makes it the world's oldest teenager! Remember: unicorns aren't real and neither is this place.
 












anonymous said:
Is this the reason for the hold up in hiring? I was contacted four months ago by a recruiter for a regional reimbursement director role. I had three interviews, completed the survey and....wait for it...nothing. In the meantime I just accepted another offer.

I'm sure this might be a good role and a great company but I've moved on!
Click to expand...

Good for you pal. That said any job in Intarcia is shitty and concerns are growing bout botched launch with no clear pathway and strategy from payers POV. At best MCOs will wait, demand more data not to mention rock bottom price in par with other pens and use Teva's generic exenatide (same as ITCA) to squeeze more out of GLP-1 purveyors.
 






anonymous said:
Good for you pal. That said any job in Intarcia is shitty and concerns are growing bout botched launch with no clear pathway and strategy from payers POV. At best MCOs will wait, demand more data not to mention rock bottom price in par with other pens and use Teva's generic exenatide (same as ITCA) to squeeze more out of GLP-1 purveyors.
Click to expand...

I get it. Everyone thinks the payers will be the gatekeepers. Yes, provided primary care docs are willing to do the procedure to insert the device. I don't know any PCPs that routinely make sterile incisions on their patients. And yet everyone is convinced that by certifying a doc that they'll be doing these ten times a day. Perfectly, no less!

Hello, complications. Hello, botched jobs. Hello, liability insurance. Hello, infections. Hello, removals. Hello, prior authorization denials. Hello, claims appeals. Hello, hello? Anybody home on the 13th floor?

I'm outta here!
 






anonymous said:
I get it. Everyone thinks the payers will be the gatekeepers. Yes, provided primary care docs are willing to do the procedure to insert the device. I don't know any PCPs that routinely make sterile incisions on their patients. And yet everyone is convinced that by certifying a doc that they'll be doing these ten times a day. Perfectly, no less!

Hello, complications. Hello, botched jobs. Hello, liability insurance. Hello, infections. Hello, removals. Hello, prior authorization denials. Hello, claims appeals. Hello, hello? Anybody home on the 13th floor?

I'm outta here!
Click to expand...
Hello, late night calls. Hello, no shows. Hello, 1 claim and the malpractice insurance premium sky rocket. Hello, known and well documented nasty nausea side effects. Hello, pts demanding to remove foreign sticks from their tummy ASAP and conundrum of who will pay for the procedure with docs likely hung out to dry. Not worth it!
 






anonymous said:
EXSCEL: No CV Benefit, but No Harm With Bydureon in Diabetes
Lisa Nainggolan
May 25, 2017
The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial involved 14,000 people with type 2 diabetes at a wide range of cardiovascular risk, from 35 countries, and randomized them to once-weekly exenatide (2 mg subcutaneously) or placebo on top of usual care. Exenatide met the goal of cardiovascular safety but failed to show any cardiovascular benefit.
"Fewer cardiovascular events were observed in the Bydureon arm of the trial; however, the efficacy objective of a superior reduction in major adverse cardiovascular events did not reach statistical significance," AstraZeneca said.It adds that the full results of EXSCEL will be reported on September 14, at the European Association for the Study of Diabetes meeting in Lisbon, Portugal.
Showing CV Benefit Is the New Norm in Type 2 Diabetes
Therefore, the fact that EXSCEL has failed to show any cardiovascular benefit with exenatide when other trials of GLP-1 agonists have shown this to be the case will be viewed as somewhat disappointing. This failure is likely to reduce the use of exenatide for the treatment of diabetes.
Click to expand...

NOVO TO DOMINATE RUN AWAY . RUN AWAY . RUN AWAY

Novo Nordisk announced that the FDA approved a new indication for Victoza (liraglutide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes and cardiovascular disease. The indication is based on the results from the LEADER trial, which demonstrated that Victoza statistically significantly reduced (-13%) the risk of cardiovascular death, heart attack or non-fatal stroke vs placebo, when added to standard of care. (Source Novo Nordisk)
 


















Wait for our oral ! Oh yeah it's just a year away

Novo is working on a longer-acting product the company reported positive results from the Phase 3 SUSTAIN 7 study showing two doses of its once-weekly candidate semaglutide significantly outperformed Trulicity in lowering glycosylated hemoglobin levels. The company submitted a New Drug Application for subcutaneous semaglutide in December and is currently conducting a late-stage study for an oral version slated to complete next summer.

So forget calling me back. Yes it was fun waiting and waiting to hear. Thank God I stayed put.
 






anonymous said:
Wait for our oral ! Oh yeah it's just a year away

Novo is working on a longer-acting product the company reported positive results from the Phase 3 SUSTAIN 7 study showing two doses of its once-weekly candidate semaglutide significantly outperformed Trulicity in lowering glycosylated hemoglobin levels. The company submitted a New Drug Application for subcutaneous semaglutide in December and is currently conducting a late-stage study for an oral version slated to complete next summer.

So forget calling me back. Yes it was fun waiting and waiting to hear. Thank God I stayed put.
Click to expand...

Indeed game changer with 3rd entrant to the weekly GLP-1 arena with better results than Trulicity and no doubt AZ's Bydureon. Sanofi is reported to be planning PH III of monthly GLP-1 licensed from Hanmi.

Oral peptide delivery is the holy grail of drug formulation and Novo has been at it for a while. Novo started the Phase III 2 years ago and still going on strong with completion of clinical trials by next summer meaning it must be going well...

All these progress by the big pharma only point to 1 thing - Intarcia ITCA is doomed to FAIL. No wonder this soon to get slaughtered unicorn is reported to be running low on cash yet unable/won't do an IPO as it means Sarbane Oxley and can't hide the weenies!
 






Novo already built new $2 billion plants in NC and Denmark to make the daily GLA-1 oral solid dosage. In the mean time Intarcia's plant is located in leased warehouse type business park in Hayward and not even a sign outside the building. BTW - there is constant dust everywhere due to concrete and road sweeping recycling plant nearby. Atta boys! That's the ticket - pathetic pharma plant next to concrete recycle plant!

Link to article from Diatribe: https://diatribe.org/novo-nordisk-begin-phase-3-clinical-trials-oral-glp-1-drug

Indeed, moving from an injection to a pill is a difficult and complicated process – and one that will require a lot of work from Novo Nordisk. On that note, the company separately announced yesterday that it will be investing $2 billion (!) for new production facilities in North Carolina (creating nearly 700 new jobs) and Denmark, part of which will go directly towards making this GLP-1 pill a reality. Starting in 2016, Novo Nordisk will be initiating seven clinical trials – including a cardiovascular outcomes trial – to test the safety and efficacy of the oral GLP-1.
 


















anonymous said:
The greatest perils for Intarcia are within with nasty mean spirited politics and complete lack of trust in every levels. Never seen such dysfunction, angst, chaos and back-stabbing in a company. Most employees are just in it for the paychecks while looking to leave. Even very well paid army of consultants are looking for exists.
Click to expand...

You are all jealous and mean. We are lucky to be a part of a new kind of biotech that is saving lives. Did you ever stop long enougnh to apreciate how much this means to be in on a whole new way to treat deseases. Please stop with the whining and complaining about something that you must be to stupid to unnerstand.
 






anonymous said:
You are all jealous and mean. We are lucky to be a part of a new kind of biotech that is saving lives. Did you ever stop long enougnh to apreciate how much this means to be in on a whole new way to treat deseases. Please stop with the whining and complaining about something that you must be to stupid to unnerstand.
Click to expand...
Wow your intelligence and piss poor spelling really shines thru chump and may I sat typical losers hired by Intarcia dumb ass.
 






Top Bottom
Back
Quote